

Site of Care

January 2020

The Site of Care drug program identifies members who are receiving certain intravenous specialty drugs at a higher cost site of service (i.e., hospital outpatient setting) and requires them to move to an equally appropriate, alternative site of service (infusion center or home). The drugs on this list are the only drugs that are part of the program and only certain members are identified for the program based on where they are currently receiving their specialty drug.

Drugs on this list also require prior authorization (PA) under the **medical benefit** through our Specialty Medical Benefit Management (SMBM) program. To start the PA process, providers should sign into the health plan's provider website to access the online medical prior authorization system. Providers can also request prior authorization by calling 877-440-0089 or faxing requests to 612-367-0742. A PA does **not** guarantee eligibility or payment of a claim. Provider specialty is considered when reviewing all medical and self-administered drug prior authorization requests.

This list may change or expand from time to time without prior notice.

Actemra (IV)	Entyvio	Krystexxa	Remicade
Aldurazyme	Epoprostenol Sodium	Lemtrada	Renflexis
Aralast NP	Fabrazyme	Lumizyme	Simponi Aria
Benlysta	Flebogamma DIF	Myozyme	Soliris
Bivigam	Gammagard	Naglazyme	Stelara (IV)
Carimune NF	Gammaked	Ocrevus	Tysabri
Cerezyme	Gammaplex	Octagam	Veletri
Cytogam	Gamunex-C	Orencia (IV)	Vimizim
Elaprase	Glassia	Privigen	Vpriv
Elelyso	Inflectra	Prolastin-C	Zemaira

